Dirk Busch, Prof. Dr. med.
Technical University of Munich Germany
Prof. Dr. med. Dirk Busch joined Immatics Scientific Advisory Board in 2021.
Dirk Busch studied human medicine at the Universities of Mainz and Freiburg, and completed his doctor’s degree in medicine in 1993. Dirk Busch studied human medicine at the Universities of Mainz and Freiburg, and completed his doctor’s degree in medicine in 1993. This was followed by his residency and postdotoral studies at the Children’s Hospital of the University of Würzburg from 1994 until 1996 and at the Section of Infectious Diseases and Immunobiology at the Yale University in New Haven/USA from 1996 until 1999. From there he joined the Technical University of Munich (TUM) where he finished in 2005 his clinical specialization in Medical Microbiology and Infection Epidemiology, and started his own independent research work as principal investigator. He gained his habilitation from TUM in 2001. From 2004 until 2008 he was C3-Professor for Medical Microbiology and Immunology at TUM. Since 2009 he has been Full Professor and Director of the Institute for Medical Microbiology, Immunology and Hygiene at TUM. His research centers on antigen-specific T cells and the development of technologies to make immune cells usable for diagnostic and cell therapy applications, including synthetic cellular immunity. He is author of more than 300 articles, many of which were published in top international journals. In addition, he is co-founder of the spin-off companies STAGE celltherapeutics (now Juno/BMS) and T Cell Factory B.V. (now Kite/Gilead).
Currently, Dirk Busch is Co-Speaker of the German Center for Infection Research (DZIF) and member of the German National Academy of Sciences Leopoldina.
(Copyright Picture: A. Eckert/TUM)
Back
Dirk Busch studied human medicine at the Universities of Mainz and Freiburg, and completed his doctor’s degree in medicine in 1993. Dirk Busch studied human medicine at the Universities of Mainz and Freiburg, and completed his doctor’s degree in medicine in 1993. This was followed by his residency and postdotoral studies at the Children’s Hospital of the University of Würzburg from 1994 until 1996 and at the Section of Infectious Diseases and Immunobiology at the Yale University in New Haven/USA from 1996 until 1999. From there he joined the Technical University of Munich (TUM) where he finished in 2005 his clinical specialization in Medical Microbiology and Infection Epidemiology, and started his own independent research work as principal investigator. He gained his habilitation from TUM in 2001. From 2004 until 2008 he was C3-Professor for Medical Microbiology and Immunology at TUM. Since 2009 he has been Full Professor and Director of the Institute for Medical Microbiology, Immunology and Hygiene at TUM. His research centers on antigen-specific T cells and the development of technologies to make immune cells usable for diagnostic and cell therapy applications, including synthetic cellular immunity. He is author of more than 300 articles, many of which were published in top international journals. In addition, he is co-founder of the spin-off companies STAGE celltherapeutics (now Juno/BMS) and T Cell Factory B.V. (now Kite/Gilead).
Currently, Dirk Busch is Co-Speaker of the German Center for Infection Research (DZIF) and member of the German National Academy of Sciences Leopoldina.
(Copyright Picture: A. Eckert/TUM)